BioStock: CombiGene's CEO on this summer's news
The gene therapy company CombiGene ended July with two significant pieces of news. Firstly, the company has started GMP production of the drug candidate CG01 for the first clinical study that begin next year. Secondly, it has obtained patents in both the US and Russia for the candidate. BioStock got in touch with CEO Jan Nilsson to find out more.
Read the full interview with Jan Nilsson at biostock.se:
https://www.biostock.se/en/combigenes-ceo-on-this-summers-news/
This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/